Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LX211 dose-ranging study in active sight-threatening non-infectious uveitis
2006-006545-13Phase 2Completed
- Sponsor
- Lux Biosciences, Inc.
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in noninfectious uveitis (NIU), cyclitis, Hyalitis and 1 more comparing LX211 with Placebo (2 arms). Primary endpoints: Mean change from baseline in graded anterior chamber cells, Rescue therapy criterion: increase in anterior chamber cell grade and 1 more. Started Jan 2007; status: completed.
02
Drugs
voclosporin
03
Conditions
noninfectious uveitis (NIU)cyclitisHyalitispanuveitis
Beyond the preview
Go deeper on 2006-006545-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006545-13.